Beijing Walvax Innovative Biotechnology

Beijing Walvax Innovative Biotechnology is a specialized research and development subsidiary of Walvax Biotechnology, focusing on the advancement of next-generation vaccine technologies. The company is a key player in China's mRNA vaccine landscape, having co-developed one of the country's first mRNA COVID-19 vaccines in collaboration with Abogen Biosciences and the Academy of Military Medical Sciences. Beyond COVID-19, the firm leverages its innovative platforms to develop recombinant protein vaccines and monoclonal antibodies targeting high-burden infectious diseases and oncology. Its operations are central to the parent company's strategy of transitioning from traditional vaccine manufacturing to high-tech biological innovation.